Orthocell Valuation Multiples

Orthocell is valued at $122M as of October 2026, a 9.5x revenue multiple. In the last 12 months, Orthocell revenue was $10M and Orthocell EBITDA was ($9M).

Orthocell Overview

About Orthocell

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.


Founded

2006

HQ

Australia

Employees

N/A

Financials (LTM)

Revenue: $10M
EBITDA: ($9M)

EV

$92M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Orthocell Financials

Orthocell reported last 12-month revenue of $10M and negative EBITDA of ($9M).

In the same LTM period, Orthocell generated $6M in gross profit, ($9M) in EBITDA losses, and had net loss of ($6M).

Revenue (LTM)


Orthocell P&L

In the most recent fiscal year, Orthocell reported revenue of $8M and EBITDA of ($10M).

Orthocell is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (132%), and net margin of (122%).

See analyst estimates for Orthocell
LTMLast FY202320242025202620272028
Revenue$10M$8M$3M$5M$7M
Gross Profit$6M$8M$2M$3M$6M
Gross Margin63%100%72%66%86%
EBITDA($9M)($10M)($7M)($7M)($9M)
EBITDA Margin(91%)(132%)(203%)(162%)(138%)
EBIT Margin(97%)(161%)(230%)(195%)(168%)
Net Profit($6M)($10M)($5M)($6M)($8M)
Net Margin(58%)(122%)(140%)(122%)(119%)
Net Debt-($30M)---

Financial data powered by Morningstar, Inc.

Orthocell Stock Performance

Orthocell has current market cap of $122M, and enterprise value of $92M.

Market Cap Evolution


Orthocell's stock price is $0.45.

Orthocell share price decreased by 16.3% in the last 30 days, and by 41.2% in the last year.

Orthocell has an EPS (earnings per share) of $-0.04.

See more trading valuation data for Orthocell
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$92M$122M-2.7%-16.3%-12.8%-41.2%$-0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Orthocell Valuation Multiples

Orthocell trades at 9.5x EV/Revenue multiple, and (10.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Orthocell

EV / Revenue (LTM)


Orthocell Financial Valuation Multiples

As of October 16, 2026, Orthocell has market cap of $122M and EV of $92M.

Orthocell has a P/E ratio of (21.5x).

LTMLast FY202320242025202620272028
EV/Revenue9.5x11.6x26.9x20.0x13.6x
EV/EBITDA(10.4x)(8.8x)(13.3x)(12.4x)(9.8x)
EV/EBIT(9.8x)(7.2x)(11.7x)(10.3x)(8.1x)
EV/Gross Profit15.0x11.6x37.3x30.3x15.9x
P/E(21.5x)(12.6x)(25.4x)(21.6x)(15.2x)
EV/FCF(9.7x)(9.5x)39.5x(15.6x)(11.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Orthocell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Orthocell Margins & Growth Rates

Orthocell grew revenue by 71% but EBITDA decreased by 28% in the last fiscal year.

In the most recent fiscal year, Orthocell reported gross margin of 100%, EBITDA margin of (132%), and net margin of (122%).

See estimated margins and future growth rates for Orthocell

Orthocell Margins

Last FY202420252026202720282029
Gross Margin100%66%86%81%
EBITDA Margin(132%)(162%)(138%)(84%)
EBIT Margin(161%)(195%)(168%)(98%)
Net Margin(122%)(122%)(119%)(80%)
FCF Margin(123%)(128%)(122%)(88%)

Orthocell Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth71%35%47%58%
Gross Profit Growth18%23%91%49%
EBITDA Growth(28%)7%26%(4%)
EBIT Growth(35%)14%27%(8%)
Net Profit Growth(23%)17%43%6%
FCF Growth(6%)(353%)40%14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Orthocell Operational KPIs

Orthocell's Rule of 40 is (26%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Orthocell's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Orthocell
LTMLast FY202320242025202620272028
Rule of 40(18%)(26%)---
Bessemer Rule of X91%62%---
S&M Expenses to Revenue--50%66%58%
G&A Expenses to Revenue-208%82%59%146%
R&D Expenses to Revenue58%14%170%136%55%
Opex to Revenue-261%303%261%253%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Humacyte$2M($25M)53.2x33.9x(4.4x)-
Outlook Therapeutics$1M($64M)91.2x33.0x(2.0x)-
Orient Europharma Co$143M($1M)1.5x-(196.7x)-
Cellectis$73M($49M)0.6x0.7x(0.8x)(0.6x)
Acumen Pharmaceuticals-($124M)--(0.3x)(0.3x)
Semnur Pharmaceuticals-($160M)--(0.9x)-
Voyager Therapeutics$40M($126M)1.0x1.7x(0.3x)(0.4x)
Biosyent$30M$9M4.0x2.6x14.4x10.5x

This data is available for Pro users. Sign up to see all Orthocell competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Orthocell

When was Orthocell founded?Orthocell was founded in 2006.
Where is Orthocell headquartered?Orthocell is headquartered in Australia.
Who is the CEO of Orthocell?Orthocell's CEO is Paul Anderson.
Is Orthocell publicly listed?Yes, Orthocell is a public company listed on Australian Securities Exchange.
What is the stock symbol of Orthocell?Orthocell trades under OCC ticker.
When did Orthocell go public?Orthocell went public in 2014.
Who are competitors of Orthocell?Orthocell main competitors include Humacyte, Outlook Therapeutics, Orient Europharma Co, Cellectis, Acumen Pharmaceuticals, Semnur Pharmaceuticals, Voyager Therapeutics, Biosyent, NRX Pharmaceuticals, Hyloris Pharmaceuticals.
What is the current market cap of Orthocell?Orthocell's current market cap is $122M.
What is the current revenue of Orthocell?Orthocell's last 12 months revenue is $10M.
What is the current revenue growth of Orthocell?Orthocell revenue growth (NTM/LTM) is 73%.
What is the current EV/Revenue multiple of Orthocell?Current revenue multiple of Orthocell is 9.5x.
Is Orthocell profitable?No, Orthocell is not profitable.
What is the current EBITDA of Orthocell?Orthocell has negative EBITDA and is not profitable.
What is Orthocell's EBITDA margin?Orthocell's last 12 months EBITDA margin is (91%).
What is the current EV/EBITDA multiple of Orthocell?Current EBITDA multiple of Orthocell is (10.4x).
What is the current FCF of Orthocell?Orthocell's last 12 months FCF is ($9M).
What is Orthocell's FCF margin?Orthocell's last 12 months FCF margin is (97%).
What is the current EV/FCF multiple of Orthocell?Current FCF multiple of Orthocell is (9.7x).
How many companies Orthocell has acquired to date?Orthocell hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Orthocell has invested to date?Orthocell hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Orthocell

Lists including Orthocell

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial